Antineoplastic Properties of Parthenin Derivatives – The Other Faces of a Weed

  • A. Saxena
  • S. Bhusan
  • B. S. Sachin
  • R. R. Kessar
  • D. M. Reddy
  • H. M. S. Kumar
  • A. K. Saxena


A spiro-isoxazolidine derivative of parthenin namely SLPAR13 was taken up for this study which induced cell death in three human cancer cell lines namely HL-60 (acute promyelocytic leukaemia), SiHa and HeLa (cervical carcinoma) with various inhibitory concentrations. The cytotoxicity test was also done on the normal cells hGF (primary human gingival fibroblast) and the inhibitory concentration was found to be more than 10 times higher than HL-60 cells. The cell death was confirmed by cell cycle arrest exhibited by the test compounds in a concentration dependent manner in HL-60 cells. The nuclear condensation and morphological changes induced by the test compounds further marked the HL-60 cell death which was confirmed to be apoptosis by DNA ladder which is hallmark of apoptosis by the formation of 180bp fragments.


Test Compound Acute Promyelocytic Leukaemia Human Cancer Cell Line Sesquiterpene Lactone SiHa Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    S.M. Kupchan, M.A. Eakin and A.M.J. Thomas; Med. Chem. 14 (1971) 1147–1152. CrossRefGoogle Scholar
  2. 2.
    D. Mew, F. Balza, G.H.N. Towers and J.G. Levy; Plat. Med. 45 (1982) 23–27.CrossRefGoogle Scholar
  3. 3.
    A.K. Picman and G.H.N. Towers; Bioch. Syst. Eco. 11 (1983) 321–327.Google Scholar
  4. 4.
    M. Hopper, G.C. Kirby, M.M. Kulkarni, S.N. Kulkarni, B.A. Nagasampagi, M.J. O’Neill, J.D. Philipson, S.R. Rojatkar, and D.C. Warhurs; Eur. J. Med. Chem. 25 (1990) 717–723.CrossRefGoogle Scholar
  5. 5.
    M.S.K. Halmuthur, A.K. Saxena, S.C. Taneja, S.K. Singh, V.K. Sethi, S.D. Sawant, N.A. Qazi, M.R. Doma, A.H. Bandey, M. Verma,. and G.N. Qazi; US Patent (WO/2009/110007) (2009).Google Scholar
  6. 6.
    J.P. Begue and D.B. Delpon; J. Fl. Chem. 127 (2006) 992–1012.CrossRefGoogle Scholar
  7. 7.
    W. Yeow, A. Baras, A. Chua, D. Nguyen, S.Sehgal, D. Schrump, D. Nguyen; J. Tho. Card. Sur. 132 (2006) 1356–1362.CrossRefGoogle Scholar
  8. 8.
    F.M. Tadeusz, S.D. Doralyn, L.L. Sarah and P.S. Jonel; Nat. Rew. Dr. Dis. 8 (2009) 69–85. CrossRefGoogle Scholar
  9. 9.
    D.M. Reddy, N.A. Qazi, S.D. Sawant, A.H. Bandey, J. Srinivas, M. Shankar, S.K. Singh, M. Verma, G. Chashoo, A. Saxena, D.M. Mondhe, A.K. Saxena, V.K.Sethi, S.C. Taneja, G.N. Qazi and H.M.S. Kumar; Eur. J. Med. Chem. (2011) (in press).Google Scholar
  10. 10.
    S. Bhushan, A. Kumar, F. Malik, S.S. Andotra, V.K. Sethi, I.P. Kaur, S.C. Taneja, G.N. Qazi, J. Singh; Apoptosis 12 (2007) 1911–1926.CrossRefGoogle Scholar
  11. 11.
    A. Krishan; J. Cell Biol. 66 (1975) 188. CrossRefGoogle Scholar
  12. 12.
    S. Bhushan, J. Singh, J.M. Rao, A.K. Saxena and G.N. Qazi; Nitric Oxide 14 (2006)72–88.Google Scholar
  13. 13.
    A. Kumar, F. Malik, S. Bhushan, V.K. Sethi, A.K Shahi, J. Kaur, S.C. Taneja, G.N. Qazi, J. Singh; Chem. Biol. Int. 171 (2008) 332–347.CrossRefGoogle Scholar
  14. 14.
    S. Kumar; Cell Death Differ. 14 (2007) 32–43.CrossRefGoogle Scholar
  15. 15.
    R.A. Kirkland, J.A. Windelborn, J.M. Kasprzak, J.L. Franklin; J. Neurosci. 22 (2002) 6480–90.Google Scholar
  16. 16.
    S. Nagata, P. Golstein; Science 267 (1995) 1449–56.CrossRefGoogle Scholar
  17. 17.
    F. Bunz; Drug Discovery Today: Disease Mechanisms 2 (2005) 383–387.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • A. Saxena
    • 1
  • S. Bhusan
    • 1
  • B. S. Sachin
    • 2
  • R. R. Kessar
    • 1
  • D. M. Reddy
    • 3
  • H. M. S. Kumar
    • 3
  • A. K. Saxena
    • 1
  1. 1.Dept. of cancer pharmacologyIndian Institute of Integrative MedicineJammuIndia
  2. 2.Dept. of Chemical TechnologyBabasaheb Ambedkar Marathwada UniversityAurangabadIndia
  3. 3.Indian Institute of Chemical TechnologyHyderabadIndia

Personalised recommendations